The U.S. Food and Drug Administration (FDA) has issued a draft Guidance that provides additional details on the role of chemical analysis in the biocompatibility assessment of medical devices.
Issued by the FDA in mid-September and published in the Federal Register, the draft Guidance, titled “Chemical Analysis for Biocompatibility Testing of Medical Devices,” describes the recommended methodologies for chemical analysis for biocompatibility assessments.
Chemical analysis is one of several approaches that manufacturers can consider when assessing the overall biocompatibility of a medical device. Chemical analysis can reduce the time needed for biocompatibility testing while also reducing the need for animal testing.
The FDA’s Guidance on the chemical analysis for biocompatibility assessment of medical devices as published in the Federal Register is available at https://www.federalregister.gov/documents/2024/09/20/2024-21575/chemical-analysis-for-biocompatibility-assessment-of-medical-devices-draft-guidance-for-industry-and.
Comments on the draft Guidance can be files through November 19th on the Federal Rulemaking Portal at https://www.regulations.gov (Reference Docket No. FDA-2024-d-4165).
